Cellectis
CLLS
41 hedge funds and large institutions have $136M invested in Cellectis in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
3% more funds holding
Funds holding: 40 → 41 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.98% less ownership
Funds ownership: 12.54% → 11.56% (-0.98%)
26% less call options, than puts
Call options by funds: $494K | Put options by funds: $667K
63% less capital inflows, than outflows
Capital inflows: $6.38M | Capital outflows: $17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Suisse
Zurich,
Switzerland
|
+$1.43M |
| 2 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.05M |
| 3 |
Morgan Stanley
New York
|
+$906K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$664K |
| 5 |
QVT Financial
New York
|
+$605K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$6.76M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$5.85M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.34M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.19M |
| 5 |
Lazard Asset Management
New York
|
-$776K |
CLLS Hedge Fund Activity: Q2 2017 in Review
41 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q2 2017, worth a combined $136M — down 0.82% from $137M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CLLS positions and 6 closed out — a net gain of 2 holders — while 13 added to existing stakes and 10 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $1.43M. The largest seller was OrbiMed, cutting an estimated $6.76M.
- 41 institutional investors held Cellectis (CLLS) as of Q2 2017, up from 40 in Q1 2017.
- Funds reported $136M of Cellectis stock for Q2 2017, down 0.82% quarter-over-quarter.
- 8 funds opened new Cellectis positions in Q2 2017 and 6 closed out, a net change of +2 holders.
- The largest Cellectis buyer in Q2 2017 was Credit Suisse, an estimated $1.43M added.
- The largest Cellectis seller in Q2 2017 was OrbiMed, an estimated $6.76M sold.
Based on aggregated 13F filings for Q2 2017.